Lukasz Kuzma/LinkedIn
Feb 16, 2026, 14:44
Lukasz Kuzma: NOAC Monotherapy vs NOAC Plus Clopidogrel in AF Beyond One Year After DES
Lukasz Kuzma, Research Professor at University of Liverpool, shared a post on X about a recent article he and his colleague co-authored, adding:
“In our NEJM editorial with ESC Stroke Chair, we highlight the first RCT in AF more than 1 year after DES showing that NOAC monotherapy was not noninferior and statistically superior to NOAC plus clopidogrel for net adverse clinical events also with less bleeding.”
Title: Thromboprophylaxis for Atrial Fibrillation in Patients with Drug-Eluting Stents
Authors: Gregory Y.H. Lip and Lukasz Kuzma
Read the Full Article on The New England Journal of Medicine.
Stay updated with Hemostasis Today.
-
Feb 16, 2026, 14:37Riten Kumar: DOACs Effectiveness in Pediatric Cancer-Associated Thrombosis
-
Feb 16, 2026, 14:30Pat Garcia-Gonzalez։ Love as an Essential Part of the Healing Journey
-
Feb 16, 2026, 14:19Erwin Loh։ Sleep-Aligned Fasting as an Important Regulator of Cardiometabolic Health
-
Feb 16, 2026, 13:56Chokri Ben Lamine: Evans Syndrome Key Clinical Insights
-
Feb 16, 2026, 13:51Adela Castro: 2025 EULAR Guidelines Key Updates in Lupus Nephritis
-
Feb 16, 2026, 13:50Rosa Hart: Stop Waiting For A Seat And Start Shaping The Table
-
Feb 16, 2026, 13:49Harprit Singh: India’s Silent Transfusion Gap – What Policymakers Need to Know in 2026
-
Feb 16, 2026, 13:46A Conversation on Gene Therapy in Hemophilia B – Irish Haemophilia Society
-
Feb 16, 2026, 13:45Nathan Connell Speaks on Gender Diversity In Haemostasis Care at EAHAD 2026